LIFE News and Press, aTyr Pharma Inc. From 12/21/20

SAN DIEGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has completed the target enrollment in its Phase 1b/2a clinic...

Halvorsen's 13F portfolio value increased from $23.14B to $27.68B. The number of positions increased 71 to 86. Viking Global increased Microsoft, Mecadolibre, and CME Group while reducing Amazon.com and dropping Uber Technologies & JD.com. The top three positions are Microsoft...

Gainers: Sonoma Pharmaceuticals (SNOA) +87%.aTyr Pharma (LIFE) +65%.NantHealth (NH) +63%.vTv Therapeutics (VTVT) +55%.Equus Total Return (EQS) +45%Hancock Jaffe Laboratories (HJLI) +34%.MDJM (MDJH) +25%.Foresight Autonomous (FRSX) +23%.Solid Biosciences (SLDB) +22%.22...

Gainers: Sonoma Pharmaceuticals (SNOA) +114%. NantHealth (NH) +110%. vTv Therapeutics (VTVT) +59%. aTyr Pharma (LIFE) +33%. NantKwest (NK) +22%.Losers: SELLAS Life Sciences (SLS) -33%. Immutep (IMMP) -29%. Salarius Pharmaceuticals (SLRX) -29%. Nabriva Therapeutics (NBRV) -29%. ALX O...

vTv Therapeutics VTVT +128% as MacAndrews & Forbes buys 625K shares.Sonoma Pharmaceuticals SNOA +122% on Crown Laboratories partnership.FAT Brands FAT +60% on plan to merge with controlling shareholder Fog Cutter Capital.Lexicon Pharmaceuticals LXRX +38%...

In the past few weeks, we have seen a great amount of bullish interest in penny stocks . Specifically, there are a few key markets that have seen more bullish growth than others. First, we have biotech penny stocks. These companies have experienced growth in the past six months due to t...

aTyr Pharma, Inc. (LIFE) Q3 2020 Earnings Conference Call November 12, 2020, 17:00 ET Company Participants Ashlee Dunston - Director, Investor Relations and Corporate Communications Sanjay Shukla - President, CEO & Director Jill Broadfoot - CFO Conference Call Participants Hartaj Singh - ...

aTyr Pharma (LIFE): Q3 GAAP EPS of -$0.68 beats by $0.06.Revenue of $0.15M (-16.7% Y/Y) beats by $0.05M.Had $36.1M in cash, equivalents and investments.Press Release For further details see: aTyr Pharma EPS beats by $0.06, beats on revenue

C omplete s e nrollment of ATYR1923 c linical t rial in patients with COVID-19 s evere r espiratory c omplications . Topline data is expected at turn of calendar year. Announce s Investigationa...

Peer-reviewed paper supports aTyr’s antibody program . Research conducted in collaboration with AbCellera Biologics, Inc. SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery an...